Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: AMP activated protein kinase therapeutics - Poxel

Drug Profile

Research programme: AMP activated protein kinase therapeutics - Poxel

Alternative Names: AMPK activators - Poxel

Latest Information Update: 12 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Poxel
  • Class
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Adrenoleucodystrophy; Adrenomyeloneuropathy

Most Recent Events

  • 09 Jul 2021 Early research in Adrenomyeloneuropathy in France (unspecified route) before July 2021 (Poxel Pharma pipeline, July 2021)
  • 22 Oct 2020 AMP-activated protein kinase therapeutics - Poxel is available for licensing as of 22 Oct 2020. https://www.poxelpharma.com/en_us/about (Poxel website, October 2020)
  • 22 Oct 2020 Early research in Adrenoleucodystrophy in France (unspecified route) before October 2020 (Poxel pipeline, October 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top